Monday, April 06, 2026

In Detail Full day, Monday, April 06, 2026, Timezone: America/Chicago

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B to Expand Rare Disease Portfolio

oncodaily - Neurocrine Biosciences has entered into a definitive agreement to acquire Soleno Therapeutics, marking a strategic expansion into rare disease treatments and strengthening its late-stage pipeline. The deal signals continued consolidation […]

AI Summary: Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $2.9 billion, picking up Soleno’s Prader‑Willi treatment candidate and bolstering its rare‑disease portfolio. The purchase folds Soleno’s clinical assets and research teams into Neurocrine, positioning the buyer to commercialize a potential high‑value therapy while shoring up long‑term pipeline growth.

Anthropic acquires stealth AI startup Coefficient Bio in $400M deal: reports

fiercehealthcare - AI powerhouse Anthropic is continuing its push into the healthcare arena with the acquisition of previously stealth AI startup Coefficient Bio in a $400 million stock deal, according to reporting from The Information and Eric Newcomer.

AI Summary: Anthropic has acquired stealth biotech Coefficient Bio in a reported $400 million deal, signaling a major push by an AI developer into drug discovery. The acquisition folds computational prowess into wet‑lab capabilities, reshaping who might lead future therapeutic discovery and prompting competitors to wonder if they missed the memo.

Can a single therapy session make a difference? Yes, with the right mindset

abcnews - Can a single therapy session make a difference

AI Summary: Experts report that a single, well‑structured therapy session can produce meaningful short‑term benefits for some patients when expectations, mindset, and therapeutic focus align. It’s not a miracle cure, but the finding nudges clinicians and policymakers toward pragmatic, low‑burden interventions that can provide rapid relief while longer‑term care is arranged.